Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-019-4651-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Investigation of the Changes in Blood Cell Components following the Administration of Pegfilgrastim in Neo-Adjuvant and Adjuvant FEC Chemotherapy for Breast Cancer].
Gan To Kagaku Ryoho
September 2024
Dept. of Pharmacy, The Cancer Institute Hospital.
Article Synopsis
- Perioperative FEC therapy is a common treatment for breast cancer, but over 20% of patients experience febrile neutropenia (FN), which pegfilgrastim is often used to prevent.
- A study on pegfilgrastim's long-term safety found no significant differences in blood cell counts or long-term effects after one year of use.
- Pegfilgrastim administration significantly reduced the incidence of FN (6.5% with pegfilgrastim vs. 22.8% without), indicating it can be safely used for one year in breast cancer patients undergoing chemotherapy.
Demonstration of physicochemical and functional similarity between Stimufend (pegfilgrastim-fpgk) and Neulasta (pegfilgrastim): A comparative analytical assessment.
PLoS One
October 2024
Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland.
Background: Pegfilgrastim is a long-acting recombinant human granulocyte colony-stimulating factor biologic that is indicated to reduce the incidence of infections, manifested by febrile neutropenia, in patients receiving myelosuppressive anti-cancer drugs and to increase survival in patients acutely exposed to myelosuppressive doses of radiation. Due to the high cost of biologic therapy and the scarcity of biosimilar alternatives, there is an unmet medical need for targeted biologics.
Objective: This comparative analytical investigation aimed to confirm the similarity of biosimilar Stimufend® (pegfilgrastim-fpgk) to reference product Neulasta® (pegfilgrastim).
A retrospective single institutional analysis of outpatient chemotherapy in patients with cancer during the COVID-19 pandemic.
Glob Health Med
August 2024
Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Providing treatment to patients with cancer, even during the coronavirus disease (COVID-19) pandemic, is essential. In collaboration with infectious disease specialists, we established guidelines for the management of patients with cancer receiving ambulatory treatment during the pandemic on April 8, 2020. This study examined the practice and management of ambulatory chemotherapy under emergency conditions.
View Article and Find Full Text PDFCost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study.
Yakugaku Zasshi
September 2024
Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research.
Article Synopsis
- A study investigated the costs and survival outcomes associated with pegfilgrastim prophylaxis for febrile neutropenia (FN) in breast cancer patients undergoing chemotherapy in Japan.
- The pegfilgrastim group had higher median total medical costs compared to the non-pegfilgrastim group but did not show a significant difference in FN hospitalization costs.
- Despite increased costs, there was no significant difference in 3-year overall survival rates between the two groups, suggesting pegfilgrastim should be used selectively based on individual FN risk factors rather than routinely.
[The Utility of Primary Prophylaxis with Pegfilgrastim in Combination with Polatuzumab Vedotin Therapy].
Gan To Kagaku Ryoho
July 2024
Dept. of Pharmacy, Suita Municipal Hospital.
Article Synopsis
- Polatuzumab vedotin (Pola) combination therapy is being studied for its effectiveness in treating diffuse large B-cell lymphoma (DLBCL), with more than 90% of patients receiving G-CSF as primary prophylaxis.
- The study found that febrile neutropenia (FN) incidence was 0% with Pola-BR therapy with G-CSF, compared to 9.5% without it, while Pola-R-CHP had rates of 0% and 31.2% respectively.
- Hospital stays were notably shorter for the Pola-BR group using G-CSF (11 days) compared to those not using it (18 days), indicating that prophylaxis may help reduce
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!